Clinical trials located in

Lancaster

Lancaster city is located in United Kingdom. Currently, 7 clinical trials are being conducted in this city.

Lancaster, a city in the United Kingdom, is steeped in history, dating back to Roman times. It is home to the majestic Lancaster Castle, which has witnessed trials of the Pendle witches and served as a prison until 2011. The city’s Georgian architecture, alongside the tranquil Lancaster Canal, adds to its historic charm. Lancaster University, recognized globally, contributes to the city’s vibrant academic atmosphere. The city also played a pivotal role during the English Civil War, underlining its significant historical importance.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Testing astegolimab’s effectiveness in chronic obstructive pulmonary disease patients

    A clinical research study is being conducted to examine the efficacy and safety of a novel treatment known as astegolimab in the management of Chronic Obstructive Pulmonary Disease (COPD). The study is particularly focused on individuals with a history of COPD who are either current or former smokers and have experienced frequent exacerbations. Within the scope of this study, astegolimab’s therapeutic potential is being compared to that of a placebo. Participants enrolled in the trial will be administered the study medication at intervals of either every 2 or 4 weeks. Key parameters under evaluation include the frequency of COPD exacerbations, variations in the quality of life of the participants, and changes in lung function over the course of the study. The study aims to contribute valuable data to medical research, particularly in understanding the treatment dynamics of astegolimab in COPD management.

    • Astegolimab
  • Breast cancer treatment study: Dato-DXd and durvalumab

    This clinical trial is a comprehensive study aimed at evaluating the effectiveness and safety of advanced treatments for breast cancer, specifically targeting triple-negative and hormone receptor-low/HER2-negative types. The study involves two groups of participants. One group will receive a combination of Dato-DXd and durvalumab as a neoadjuvant (pre-surgery) treatment, followed by durvalumab as an adjuvant (post-surgery) therapy, with or without additional chemotherapy. The other group will be treated with pembrolizumab plus chemotherapy as both neoadjuvant and adjuvant therapies. The goal is to see which method is better at treating the cancer. Additional objectives include evaluating overall survival, distant disease-free survival, and participant-reported outcomes related to symptoms, physical function, fatigue, and quality of life.

    • Epirubicin
    • Doxorubicin
    • Dato-DXd
    • Carboplatin
    • Pembrolizumab
    • olaparib
    • Capecitabine
    • Durvalumab
    • Cyclophosphamide
    • Paclitaxel
  • Comparing camizestrant with standard therapy in early breast cancer treatment

    This study, known as CAMBRIA-2, aims to test a medication called Camizestrant for treating early-stage breast cancer that is ER+ and HER2-. It will compare Camizestrant with the standard treatments currently used, which are either Aromatase Inhibitor or Tamoxifen. The study is specifically focused on patients with ER+/HER2- breast cancer who are at high or medium-high risk of their cancer returning. Before they can participate, these patients must have finished all planned cancer treatments, such as surgery or chemotherapy, and currently show no signs of the disease. The main goal of the study is to see whether Camizestrant helps to prevent breast cancer from coming back. This would be measured by looking at the time from when patients join the study to when they first see their breast cancer return, or unfortunately, pass away. The study also aims to see whether Camizestrant improves other measures, such as overall survival and quality of life.

    • camizestrant
    • Abemaciclib
    • Anastrozole
    • Letrozole
    • Exemestane
    • tamoxifen
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in United Kingdom:

.